1. Shomali W, Gotlib J. World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management. Am J Hematol. 2019;94:1149–67.
2. Butt NM, Lambert J, Ali S, Beer PA, Cross NC, Duncombe A, et al. Guideline for the investigation and management of eosinophilia. Br J Haematol. 2017;176:553–72.
3. Helbig G, Soja A, Bartkowska-Chrobok A, Kyrcz-Krzemień S. Chronic eosinophilic leukemia-not otherwise specified has a poor prognosis with unresponsiveness to conventional treatment and high risk of acute transformation. Am J Hematol. 2012 Jun;87(6):643–5.
4. Pohlkamp C, Vetro C, Dicker F, Meggendorfer M, Kern W, Haferlach C, et al. Evidence of clonality in cases of hypereosinophilia of undetermined significance. Leuk Lymphoma. 2019 Aug;60(8):2071–4.
5. Patel AB, Franzini A, Leroy E, Kim SJ, Pomicter AD, Genet L, et al. JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera. Blood. 2019 Dec 26;134(26):2388–98.